GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update
GRAIL (Nasdaq: GRAL) reported Q2 2024 financial results, showing 43% year-over-year revenue growth to $32.0 million. The company faced a net loss of $1.59 billion, including a $1.42 billion goodwill and intangible impairment. GRAIL's adjusted gross profit increased 66% to $16.0 million, while adjusted EBITDA was $(139.4) million.
Key highlights include enrollment in the REACH study, completion of PATHFINDER 2 study enrollment, and final study visits for the NHS-Galleri trial. GRAIL announced a strategic restructuring, reducing headcount by 30% and focusing on core multi-cancer early detection priorities. These measures are expected to extend the company's cash runway into 2028 and reduce burn to $325 million in 2025.
GRAIL (Nasdaq: GRAL) ha pubblicato i risultati finanziari del secondo trimestre 2024, con un crescita del fatturato del 43% anno su anno, raggiungendo i 32,0 milioni di dollari. L'azienda ha registrato una perdita netta di 1,59 miliardi di dollari, che include un impairment di goodwill e attività immateriali di 1,42 miliardi di dollari. Il profitto lordo rettificato di GRAIL è aumentato del 66%, arrivando a 16,0 milioni di dollari, mentre l'EBITDA rettificato è stato di $(139,4) milioni.
I punti salienti includono l'iscrizione allo studio REACH, il completamento dell'arruolamento nello studio PATHFINDER 2 e le visite finali del trial NHS-Galleri. GRAIL ha annunciato una ristrutturazione strategica, riducendo il personale del 30% e concentrandosi sulle priorità fondamentali della rilevazione precoce di diversi tipi di cancro. Queste misure dovrebbero prolungare la liquidità dell'azienda fino al 2028 e ridurre il burn a 325 milioni di dollari nel 2025.
GRAIL (Nasdaq: GRAL) reportó los resultados financieros del segundo trimestre de 2024, mostrando un crecimiento de ingresos del 43% interanual que alcanzó los 32,0 millones de dólares. La compañía enfrentó una pérdida neta de 1,59 mil millones de dólares, incluyendo una disminución de 1,42 mil millones de dólares en goodwill y activos intangibles. El beneficio bruto ajustado de GRAIL aumentó un 66% hasta 16,0 millones de dólares, mientras que el EBITDA ajustado fue de $(139,4) millones.
Los aspectos destacados incluyen la inscripción en el estudio REACH, la finalización de la inscripción en el estudio PATHFINDER 2 y las visitas finales del ensayo NHS-Galleri. GRAIL anunció una reestructuración estratégica, reduciendo el personal en un 30% y enfocándose en las prioridades fundamentales de la detección temprana de múltiples tipos de cáncer. Se espera que estas medidas extiendan la liquidez de la empresa hasta 2028 y reduzcan la quema a 325 millones de dólares en 2025.
GRAIL (Nasdaq: GRAL)은 2024년 2분기 재무 결과를 보고했으며, 전년 대비 43% 매출 성장을 기록하여 3200만 달러에 도달했습니다. 회사는 15억 9천만 달러의 순손실을 입었으며, 이에는 14억 2천만 달러의 goodwill 및 무형자산 손상분이 포함됩니다. GRAIL의 조정된 총 이익은 66% 증가하여 1600만 달러에 이르렀으며, 조정된 EBITDA는 $(1억 3,940만) 달러였습니다.
주요 하이라이트에는 REACH 연구 참여, PATHFINDER 2 연구 참여 완료 및 NHS-Galleri 시험 최종 방문이 포함됩니다. GRAIL은 전략적 구조조정을 발표하고 인력을 30% 축소하며 핵심 다중 암 조기 발견 우선 순위에 집중할 것입니다. 이러한 조치는 회사의 현금 지속 기간을 2028년까지 연장하고 2025년까지 소모를 3억 2500만 달러로 줄이는 데 기여할 것으로 예상됩니다.
GRAIL (Nasdaq: GRAL) a annoncé les résultats financiers du deuxième trimestre 2024, affichant une croissance des revenus de 43% d'une année sur l'autre, pour atteindre 32,0 millions de dollars. L'entreprise a subi une perte nette de 1,59 milliard de dollars, comprenant une dépréciation de goodwill et d'actifs incorporels de 1,42 milliard de dollars. Le bénéfice brut ajusté de GRAIL a augmenté de 66% pour atteindre 16,0 millions de dollars, tandis que l'EBITDA ajusté a été de $(139,4) millions.
Parmi les points forts, on note l'inscription à l'étude REACH, l'achèvement de l'inscription à l'étude PATHFINDER 2, et les visites finales de l'essai NHS-Galleri. GRAIL a annoncé une restructuration stratégique, réduisant l'effectif de 30% et se concentrant sur les priorités centrales de détection précoce de plusieurs cancers. Ces mesures devraient prolonger la capacité financière de l'entreprise jusqu'en 2028 et réduire la consommation à 325 millions de dollars en 2025.
GRAIL (Nasdaq: GRAL) hat die Finanzzahlen für das zweite Quartal 2024 veröffentlicht und ein Umsatzwachstum von 43% im Vergleich zum Vorjahr auf 32,0 Millionen US-Dollar verzeichnet. Das Unternehmen erlitt einen Nettoverlust von 1,59 Milliarden US-Dollar, einschließlich einer Wertminderung von 1,42 Milliarden US-Dollar auf Goodwill und immaterielle Vermögenswerte. Der bereinigte Bruttogewinn von GRAIL stieg um 66% auf 16,0 Millionen US-Dollar, während das bereinigte EBITDA $(139,4) Millionen betrug.
Zu den wichtigsten Punkten gehören die Einschreibung in die REACH-Studie, der Abschluss der Teilnehmeraufnahme in die PATHFINDER 2-Studie und die abschließenden Studienbesuche für die NHS-Galleri-Studie. GRAIL kündigte eine strategische Umstrukturierung an, die die Mitarbeiterzahl um 30% reduzieren und sich auf die Kernprioritäten der frühzeitigen Erkennung mehrerer Krebsarten konzentrieren wird. Diese Maßnahmen sollen die finanzielle Stabilität des Unternehmens bis 2028 verlängern und den Verlust auf 325 Millionen US-Dollar im Jahr 2025 senken.
- Revenue growth of 43% year-over-year to $32.0 million
- Adjusted gross profit increased 66% to $16.0 million
- Cash and cash equivalents totaled $958.8 million as of June 30, 2024
- Strategic restructuring expected to extend cash runway into 2028
- Completed enrollment of over 35,000 participants in PATHFINDER 2 study
- Net loss increased by 721% to $1.59 billion
- Gross loss of $(17.9) million
- Adjusted EBITDA decreased by 2% to $(139.4) million
- Reducing headcount and planned hires by approximately 30%
- Substantially decreasing investment in product programs beyond Galleri
Insights
GRAIL's Q2 2024 results show mixed signals. While revenue grew
The company's strategic restructuring, including a
GRAIL's progress in cancer detection studies is noteworthy. The REACH study targeting Medicare beneficiaries addresses a important demographic for early cancer detection. The completion of enrollment in the PATHFINDER 2 study with over 35,000 participants and the final study visits for the NHS-Galleri trial with over 140,000 participants are significant milestones. These large-scale trials could provide robust data on Galleri's efficacy and potentially revolutionize cancer screening protocols.
However, the company's decision to substantially decrease investment in product programs beyond Galleri is a double-edged sword. While it allows focus on their flagship product, it might limit GRAIL's ability to diversify and adapt to future market needs in the rapidly evolving field of cancer diagnostics.
GRAIL's market position in multi-cancer early detection (MCED) appears strong, with over 215,000 Galleri tests sold. The company's strategy to establish Galleri as a complement to existing single-cancer screenings could create a new standard of care, potentially leading to significant market expansion. However, the reduction in commercial organization size might slow down market penetration in the short term.
The focus on biopharmaceutical partnerships for leveraging GRAIL's proprietary methylation technology in precision oncology applications is promising. This could open up new revenue streams and solidify GRAIL's position in the broader oncology market. Investors should watch for developments in these partnerships and their potential impact on future revenue diversification.
Second Quarter Revenue Grew
Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028
Revenue in the second quarter was
"GRAIL completed the separation from Illumina on June 24, 2024, and we are pleased to report our quarterly results for the first time as an independent public company. In the second quarter of 2024, GRAIL continued to deliver
For the three months ended June 30, 2024, as compared to the three months ended July 2, 2023, GRAIL reported:
- Revenue: Total revenue, comprised of screening and development services revenue, was
$32.0 million $9.6 million 43% . - Net loss: Net loss was
$1.59 billion $1.39 billion 721% . Net loss includes goodwill and intangible impairment of$1.42 billion - Gross loss: Gross loss was
$(17.9) million $6.4 million 26% . - Adjusted gross profit1: Adjusted gross profit was
$16.0 million $6.4 million 66% . - Adjusted EBITDA1: Adjusted EBITDA was
$(139.4) million $2.8 million 2% . - Cash position: Cash and cash equivalents totaled
$958.8 million
Recent business highlights include:
- Commenced enrollment in the REACH study. The REACH study, also known as the Galleri-Medicare study, will enroll 50,000 individuals and allow for three annual screens to provide clinical validation and utility in the Medicare population, with a focus on health equity. Medicare beneficiaries are among those most at risk for cancer due to age and other risk factors, representing an important unmet need for early cancer detection.
- Completed enrollment of more than 35,000 participants in the registrational PATHFINDER 2 study. The PATHFINDER 2 study is a prospective, multi-center, interventional study evaluating the safety and performance of Galleri in a population of individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in
the United States . - Completed final study visits for the registrational NHS-Galleri trial. The NHS-Galleri trial is a prospective, randomized controlled clinical utility trial of over 140,000 participants between the ages of 50-77 at the time of enrollment, each of whom provided three annual blood samples to evaluate the implementation of Galleri alongside existing NHS standard of care screenings.
Strategic update:
Following a portfolio review, we are reducing our overall spend and focusing our resources on our core multi-cancer early detection ("MCED") priorities, including progress toward completion of our registrational studies and our premarket approval application submission.
As part of this restructure, we are reducing existing headcount and planned hires for 2024 by approximately
We expect these cost reductions to extend our existing cash runway from the second half of 2026 into 2028. As a result, we anticipate reducing our burn in 2025 to
Conference Call and Webcast
A webcast and conference call will be held today, Aug. 13, 2024, at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may access it on the investor relations section of GRAIL's website at investors.grail.com.
A replay of the webcast will be available on GRAIL's website for 30 days.
_____________________________ |
1 See "Non-GAAP Disclosure" and the associated reconciliations for important information about our use of non-GAAP measures. |
About GRAIL
GRAIL, Inc. is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer, to help screen for some of the deadliest cancers that don't have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com.
* Sensitivity in study participants with – Pancreas cancer:
Laboratory/Test Information
GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the
Non-GAAP Disclosure
In addition to our financial results, this press release also includes financial measures that are not calculated in accordance with
- Adjusted Gross Profit/(Loss) is a key performance measure that our management uses to assess our operational performance, as it represents the results of revenues and direct costs, which are key components of our operations. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it reflects the gross profitability of our operations, and excludes the indirect costs associated with our sales and marketing, product development, general and administrative activities, and depreciation and amortization, and the impact of our financing methods and income taxes.
We calculate Adjusted Gross Profit/(Loss) as gross profit/(loss) (as defined below) adjusted to exclude amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted Gross Profit/(Loss) should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other GAAP measures of income (loss) or profitability. The following table presents a reconciliation of gross loss, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted Gross Profit. - Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of net income (loss) to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different tax rates, different operational and ownership histories, and/or different forms of employee compensation.
Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of net income or income from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.
Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and otherU.S. GAAP measures of income (loss). Additionally, it is not intended to be a measure of free cash flow for management's discretionary use, as it does not consider certain cash requirements such as interest and tax payments. Further, our definition of Adjusted EBITDA may differ from similarly titled measures used by other companies and therefore may not be comparable among companies. The following table presents a reconciliation of net loss, the most directly comparable financial measure calculated in accordance withU.S. GAAP, to Adjusted EBITDA on a consolidated basis.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in tabular form below.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations and projections of our future financial performance, future tests or products, technology, clinical studies, regulatory compliance, potential market opportunity, anticipated growth strategies, restructuring costs, sufficiency of cash on hand to finance our business, cost savings, budgets and strategies, restructuring and stock-based compensation costs, impact of the restructuring on our operations and growth and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
GRAIL | |||
Condensed Consolidated Balance Sheets | |||
(in thousands, except for per share data) | June 30, 2024 | December 31, 2023 | |
Assets | (unaudited) | ||
Current assets: | |||
Cash and cash equivalents | $ 958,845 | $ 97,287 | |
Accounts receivables, net | 13,406 | 16,942 | |
Supplies | 25,506 | 21,695 | |
Prepaid expenses and other current assets | 20,925 | 20,141 | |
Total current assets | 1,018,682 | 156,065 | |
Property and equipment, net | 78,005 | 84,995 | |
Operating lease right-of-use assets | 74,503 | 84,386 | |
Restricted cash | 3,918 | 4,225 | |
Intangibles assets, net | 2,086,056 | 2,687,223 | |
Goodwill | — | 888,936 | |
Other non-current assets | 8,476 | 7,984 | |
Total assets | $ 3,269,640 | $ 3,913,814 | |
Liabilities and stockholders'/member's (deficit) equity | |||
Current liabilities: | |||
Accounts payable | $ 16,247 | $ 19,673 | |
Accrued liabilities | 56,573 | 73,806 | |
Incentive plan liabilities | — | 54,513 | |
Operating lease liabilities, current portion | 13,945 | 14,809 | |
Other current liabilities | 1,413 | 809 | |
Total current liabilities | 88,178 | 163,610 | |
Operating lease liabilities, net of current portion | 62,165 | 69,598 | |
Deferred tax liabilities, net | 422,163 | 32,921 | |
Other non-current liabilities | 2,007 | 1,498 | |
Total liabilities | 574,513 | 267,627 | |
Preferred stock, par value of | — | — | |
Common stock | 31 | — | |
Additional paid-in capital | 12,274,286 | — | |
Member's equity | — | 11,421,446 | |
Accumulated other comprehensive income | 1,386 | 1,066 | |
Accumulated deficit | (9,580,576) | (7,776,325) | |
Total stockholders'/member's equity | 2,695,127 | 3,646,187 | |
Total liabilities and stockholders'/member's equity | 3,269,640 | 3,913,814 | |
GRAIL | |||||||
Condensed Consolidated Statements of Operations | |||||||
(Unaudited) | |||||||
Three Months Ended | Six months ended | ||||||
(in thousands except for per share data) | June 30, 2024 | July 2, 2023 | June 30, 2024 | July 2, 2023 | |||
Revenue: | |||||||
Screening revenue | $ 28,163 | $ 20,027 | $ 51,702 | $ 35,599 | |||
Development services revenue | 3,807 | 2,387 | 6,989 | 6,458 | |||
Total revenue | 31,970 | 22,414 | 58,691 | 42,057 | |||
Costs and operating expenses: | |||||||
Cost of screening revenue (exclusive of amortization of intangible assets) | 15,789 | 11,125 | 29,511 | 21,550 | |||
Cost of development services revenue | 621 | 2,095 | 2,057 | 3,455 | |||
Cost of revenue — amortization of intangible assets | 33,472 | 33,472 | 66,944 | 66,944 | |||
Research and development | 94,196 | 88,710 | 195,821 | 174,583 | |||
Sales and marketing | 40,989 | 40,737 | 87,808 | 86,572 | |||
General and administrative | 67,258 | 50,642 | 124,327 | 97,351 | |||
Goodwill and intangible impairment | 1,420,936 | — | 1,420,936 | — | |||
Total costs and operating expenses | 1,673,261 | 226,781 | 1,927,404 | 450,455 | |||
Loss from operations | (1,641,291) | (204,367) | (1,868,713) | (408,398) | |||
Other income (expense): | |||||||
Interest income | 2,805 | 1,847 | 5,706 | 4,074 | |||
Other income (expense), net | 5 | (320) | 47 | (225) | |||
Total other income (expense), net | 2,810 | 1,527 | 5,753 | 3,849 | |||
Loss before income taxes | (1,638,481) | (202,840) | (1,862,960) | (404,549) | |||
Benefit from income taxes | 53,144 | 9,796 | 58,709 | 17,839 | |||
Net loss | $ (1,585,337) | $ (193,044) | $ (1,804,251) | $ (386,710) | |||
Net loss per share — Basic and Diluted | $ (51.06) | $ (6.22) | $ (58.11) | $ (12.45) | |||
Weighted average shares of common stock—basic and diluted | 31,049 | 31,049 | 31,049 | 31,049 | |||
GRAIL | |||
Condensed Consolidated Statements of Cash Flows | |||
(Unaudited) | |||
Six Months Ended | |||
(in thousands) | June 30, 2024 | July 2, 2023 | |
Net cash used by operating activities | $ (379,085) | $ (309,391) | |
Net cash used by investing activities | (3,934) | (5,923) | |
Net cash provided by financing activities | 1,244,300 | 303,775 | |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (30) | 257 | |
Net increase (decrease) in cash, cash equivalents, and restricted cash | $ 861,251 | $ (11,282) | |
Cash, cash equivalents and restricted cash — beginning of period | $ 101,512 | $ 246,128 | |
Cash, cash equivalents and restricted cash — end of period | $ 962,763 | $ 234,846 | |
GRAIL | |||||||
Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||
(Unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
(in thousands) | June 30, 2024 | July 2, 2023 | June 30, 2024 | July 2, 2023 | |||
Gross loss (1) | $ (17,912) | $ (24,278) | $ (39,821) | $ (49,892) | |||
Amortization of intangible assets | 33,472 | 33,472 | 66,944 | 66,944 | |||
Stock-based compensation | 463 | 450 | 944 | 823 | |||
Adjusted Gross Profit | $ 16,023 | $ 9,644 | $ 28,067 | $ 17,875 | |||
_____________ | |
(1) | Gross profit/(loss) is calculated as total revenue less cost of revenue (exclusive of amortization of intangible assets), cost of revenue—related parties, and cost of revenue—amortization of intangible assets. |
GRAIL | |||||||
Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||
(Unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
(in thousands) | June 30, 2024 | July 2, 2023 | June 30, 2024 | July 2, 2023 | |||
Net loss | $ (1,585,337) | $ (193,044) | $ (1,804,251) | $ (386,710) | |||
Adjusted to exclude the following: | |||||||
Interest income | (2,805) | (1,847) | (5,706) | (4,074) | |||
Benefit from income tax expense | (53,144) | (9,796) | (58,709) | (17,839) | |||
Amortization of intangible assets (1) | 34,583 | 34,583 | 69,167 | 69,167 | |||
Depreciation | 4,805 | 4,545 | 10,218 | 9,802 | |||
Goodwill and intangible impairment(2) | 1,420,936 | — | 1,420,936 | — | |||
Illumina/GRAIL merger & divestiture legal and professional services costs (3) | 15,624 | 3,466 | 21,932 | 8,254 | |||
Stock-based compensation (4) | 25,947 | 25,548 | 55,053 | 47,064 | |||
Adjusted EBITDA | $ (139,391) | $ (136,545) | $ (291,360) | $ (274,336) | |||
___________ | |
(1) | Represents amortization of intangible assets, including developed technology and trade names. |
(2) | Reflects impairment of the goodwill and intangible assets recognized as a result of Illumina's acquisition of the Company in August 2021 ("the Acquisition"). |
(3) | Represents legal and professional services costs associated with the Acquisition and corresponding antitrust litigation, including compliance with the hold separate arrangements imposed by the European Commission, and legal and professional services costs associated with the divestiture. |
(4) | Represents all stock-based compensation recognized on our standalone financial statements for the periods presented. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-reports-second-quarter-2024-financial-results-and-provides-a-strategic-update-302221398.html
SOURCE GRAIL, Inc.
FAQ
What was GRAIL's revenue growth in Q2 2024?
How much was GRAIL's net loss in Q2 2024?
What strategic changes did GRAIL announce in Q2 2024?
How many Galleri tests has GRAIL sold as of June 30, 2024?
What is the expected impact of GRAIL's cost reduction measures on its 2025 burn rate?
